ROCHESTER, N.Y., Oct. 1 /PRNewswire-FirstCall/ —
VirtualScopics, Inc. (Nasdaq:
VSCP), a provider of quantitative imaging for clinical trials,
today announced revenues for the third quarter ended September 30,
2010 exceeded $3.5 million, representing a greater than 25%
increase over the comparable period in 2009 and a greater than 9%
growth over the preceding quarter ended June 30, 2010. Year-to-date
revenues increased over 30% for the period ended September 30, 2010
compared to the same period in 2009.
“We are extremely pleased to deliver another quarter of record
revenue,” stated Jeff Markin, president and chief executive officer
of VirtualScopics. “Our growth this year has been spurred by the
demand for our services within later stage clinical trials and as a
result, our 2010 year-to-date clinical trial revenues have already
exceeded what we recognized for the full year in 2009.” He
added, “Our strong value proposition within the industry is one of
the main contributors to our ability to report our 13th consecutive
quarter of revenue growth.” He concluded, “We are excited about our
opportunities as we enter the fourth quarter and anticipate a solid
close to 2010.”
VirtualScopics plans to report its complete third quarter 2010
financial results on Thursday, November 11, 2010. Jeff Markin and
Molly Henderson, VirtualScopics’ Chief Business and Financial
Officer, will provide a business update and discuss the third
quarter results during the conference call that morning at 11:00
a.m. EST.
About VirtualScopics, Inc.VirtualScopics, Inc. is a leading
provider of imaging solutions to accelerate drug and medical device
development. VirtualScopics has developed a robust software
platform for analysis and modeling of both structural and
functional medical images. In combination with
VirtualScopics’ industry-leading experience and expertise i
‘/>”/>
SOURCE